THERE ARE NEW STUDIES SUPPORTING A TRIUMVERATE COCKTAIL
This update is in response to the continuing controversy regarding the importance of supplementation with carotenoids, specifically regarding the benefits of mesozeaxanthin, purportedly a semi-synthetic formulation. There have been additions to the research regarding this issue, but none-the-less the rhetoric has become quite contentious.
This study aims to develop water-soluble low molecular weight chitosan (LMWC) nanoencapsules with lutein to improve its bioavailability. Lutein-LMWC nanoencapsules were prepared, characterized and bioavailability was studied in vitro and in vivo with lutein in mixed micelles (control). The particle size ranged between 80-600nm, which was confirmed by Atomic Force Microscope. The interaction between LMWC and lutein in nanocencapsules by 1H and 13C NMR showed the essentiality of water molecules to hold the lutein between LMWC chains of nanoparticle with a reversible weak bond. Bioavailability of lutein (200μM) in vitro showed that lutein-LMWC nanoencapsules was significantly higher (27.7%) than control. Postprandial lutein level in the plasma (54.5%), liver (53.9%) and eyes (62.8%) of mice fed on nanoencapsulated lutein were higher than the control. LMWC may serve as novel carrier for enhancing the lutein bioavailability and can be suggested as the better dietary compound in food and pharmaceutical applications.
Lutein is a small-molecule carotenoid that has been studied with varying degrees of interest in both general nutrition and ophthalmology. This molecule is derived from green leafy vegetables (as well as commercially available dietary supplements) and has been postulated to act as a modulator in retinal health, specifically as a factor in the prevention of macular degeneration. The available clinical data do not suggest that lutein or the carotenoid zeaxanthin have any inherent toxicity. The presence of either or both has been linked to the prevention, but not necessarily the treatment, of macular degeneration. The available information may suggest that lutein intake as an oral supplement, coupled with awareness (and where possible modulation) of certain risk factors such as elevated body weight, smoking, and a family history of AMD, taken as part of an entire personalized treatment regimen, could positively impact the development of age-related macular degeneration.
Kemin literature updates for July 2013.
Controversy abounds in the arena of the impact of behavior and nutrition related to all disease…including glaucoma. The following is an exercise in science to attempt to bring some organization and sense to the discussion.